36,400 Shares in Qiagen N.V. $QGEN Purchased by WINTON GROUP Ltd

WINTON GROUP Ltd bought a new position in shares of Qiagen N.V. (NYSE:QGEN) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 36,400 shares of the company’s stock, valued at approximately $1,423,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Boston Partners purchased a new stake in shares of Qiagen during the 3rd quarter worth approximately $179,450,000. Norges Bank acquired a new position in Qiagen during the fourth quarter worth $166,500,000. Dimensional Fund Advisors LP acquired a new position in Qiagen during the third quarter worth $58,079,000. Price T Rowe Associates Inc. MD boosted its position in Qiagen by 12.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock worth $379,072,000 after purchasing an additional 906,589 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in Qiagen by 9.7% during the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after purchasing an additional 697,342 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Stock Up 0.6%

Shares of NYSE:QGEN opened at $42.39 on Friday. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $8.74 billion, a P/E ratio of 21.72, a P/E/G ratio of 4.23 and a beta of 0.63. Qiagen N.V. has a 52-week low of $32.53 and a 52-week high of $57.81. The stock’s fifty day simple moving average is $42.20 and its 200-day simple moving average is $40.18.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The firm had revenue of $535.04 million during the quarter, compared to analysts’ expectations of $527.50 million. During the same quarter last year, the business posted $0.60 EPS. The firm’s quarterly revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, equities research analysts forecast that Qiagen N.V. will post 2.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on QGEN. UBS Group started coverage on Qiagen in a research report on Wednesday. They issued a “neutral” rating and a $47.00 price target for the company. Stifel Nicolaus set a $40.00 target price on shares of Qiagen in a report on Friday, August 7th. Citigroup restated a “neutral” rating and set a $45.00 target price (up from $38.00) on shares of Qiagen in a research report on Monday, August 10th. TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Finally, Weiss Ratings upgraded shares of Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $43.51.

About Qiagen

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.